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Sir,
In his letter, Dr Bhatnagar challenges the claim that there were ‘no
efficacy differences between letrozole and anastrozole’. Firstly, I
would like to point out that this claim was not stated in my review
(Sainsbury, 2004). Such a statement on the relative efficacy of two
agents could only be assessed by direct comparison in a large
randomised, double-blind, clinical trial and no such data are
available for letrozole and anastrozole. It is therefore inappropriate
to reach conclusions about the relative efficacy of agents on the basis
of cross-trial comparisons. The overall claim made in the review was
that ‘Together these data suggest that once a certain threshold of
aromatase inhibition is reached, small differences in oestrogen
suppression between the third-generation aromatase inhibitors (AIs)
do not lead to clinically significant differences in overall efficacy’.
This overall claim was based on a review of the best available
evidence of clinical efficacy for the third-generation AIs as first-
and second-line therapy for advanced breast cancer. The highest
level of evidence was provided by an open-label randomised trial
comparing letrozole and anastrozole as second-line endocrine
therapy in 713 patients with advanced breast cancer (Rose et al,
2003). As described in my review, the only end point that showed a
significant difference between letrozole and anastrozole was the
secondary end point of objective response rate (19.1 vs 12.3%,
P¼0.013), although there was no difference in objective response
rate (17.3 vs 16.8%) for those patients with hormone receptor-
positive tumours (48% of the total population and the clinically
relevant target population for endocrine therapy). While, as
commented by Dr Bhatnagar, a higher likelihood of responding
to endocrine therapy is highly relevant for women with advanced
breast cancer, this result should not be overinterpreted. This trial
was an open-label trial and, therefore, open to bias particularly
with regard to subjective end points such as objective response and
tolerability. The difference in overall objective response rate did
not translate into a benefit for letrozole on the primary end point
of time to progression or any other efficacy end point, and is
perhaps, therefore, unlikely to result in the delay of other therapies
as stated by Dr Bhatnagar. While neither Dr Bhatnagar nor I can
explain why the statistically significantly higher objective response
rate was limited to the group of patients with undetermined
hormone status, the fact remains that in those patients with
hormone receptor-positive disease (the clinically relevant group of
patients), there was no statistically significant difference in
objective response between letrozole and anastrozole.
Dr Bhatnagar states in his letter that in a Phase III study in
postmenopausal women receiving first-line therapy for advanced
breast cancer, letrozole was found to be superior to tamoxifen in
all end points including a prospectively planned survival analysis
at 1- and 2-years follow-up. However, in the prospectively planned
final analysis of overall survival in this study, at a median follow-
up of 32 months, there was no significant difference in overall
survival between letrozole and tamoxifen (overall log-rank;
P¼0.53) (Mouridsen et al, 2003).
Additional truncated log-rank tests at 6-month intervals did
show nominally statistically significant differences in favour of the
randomised letrozole arm at 6, 12, 18 and 24 months, but these
were nonprotocolled, retrospectively planned analyses (albeit
planned before database lock), and were not adjusted for multiple
comparisons. As such, any findings should only be considered
exploratory as already stated by Dr Buzdar in his comments on
this study (Buzdar, 2004). The performance of the ‘gold standard’
tamoxifen treatment in this study has also been questioned
(Buzdar, 2002), highlighting again the many difficulties associated
with cross-trial comparisons.
Dr Bhatnagar also suggests that letrozole may elicit a response in
hormone receptor-negative tumours; however, there appears to be
no credible basis for this claim. While benefits with anastrozole are
most apparent in the hormone receptor-positive women who
receive first-line treatment (Bonneterre et al, 2001), its use is
indicated in those patients with undetermined hormone receptor
status because, as pointed out by Dr Bhatnagar, the majority will
be endocrine responsive due to their hormone receptor-positive
status. Further, in the overall population, anastrozole is at least
equivalent to tamoxifen in terms of median time to progression
and is associated with tolerability benefits over tamoxifen
(Bonneterre et al, 2001). In the second-line Phase III studies, both
anastrozole and letrozole were assessed only in patients with
hormone receptor-positive or unknown status.
Finally, Dr Bhatnagar queries the hypothesis that although
clinical efficacy may be unaffected by small differences in potency,
this does not preclude the fact that small differences in oestrogen Published online 15 March 2005
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suggested by Dr Bhatnagar, this statement is purely speculative. A
similar statement was made in the ASCO Expert Panel review on
adjuvant aromatase inhibitors: ‘yclosely related agents with
similar mechanisms of action may have different toxicity profiles’
(Winer et al, 2002). Dr Bhatnagar continues that the less potent AI
anastrozole has been associated with a marked increase in fracture
rates when used in early breast cancer (The ATAC Trialists’ Group,
2002, 2003), whereas letrozole has not (Goss et al, 2003). However,
the data from these studies are not comparable. While both studies
aimed to compare the safety and efficacy of the AI with tamoxifen
in postmenopausal women with early breast cancer, patients in the
letrozole trial had already completed 5 years of adjuvant tamoxifen
therapy, an agent with a mild protective effect against bone loss
due to its partial oestrogen agonist activity (Grey et al, 1995) and,
furthermore, the comparison was vs placebo, not tamoxifen as in
the ATAC trial. Nevertheless, the letrozole trial still found a higher
incidence of previously undiagnosed osteoporosis and fractures in
the letrozole group than the placebo group (Goss et al, 2003), and
the difference in osteoporosis rates was statistically significant in
the updated analysis of this trial presented at ASCO 2004 (8 vs 6%,
P¼0.003) (Goss, 2004). At a median follow-up of 37 months,
anastrozole was associated with a higher incidence of fractures
than tamoxifen in patients who received primary adjuvant therapy
for early breast cancer (7.1 vs 4.4%, Po0.001) (The ATAC Trialists’
Group, 2003); however, the fracture rate with anastrozole appears
to stabilise after reaching a peak at 2 years and the relative risk vs
tamoxifen does not worsen with continued treatment (Locker and
Eastell, 2003). Anastrozole remains the only AI with data
quantifying its effects on bone in this setting.
In summary, the available evidence does suggest that small
differences in oestrogen suppression between the third-generation
AIs do not lead to clinically significant differences in overall
efficacy as concluded in my review (Sainsbury, 2004).
‘The recently presented, but as yet unpublished, results of
the Big-Femta (1–98) study demonstrated similar effects on
bone for letrozole in the adjuvant setting. There appears to be
an, as yet unexplained, excess rate of cardiac events in the
letrozole arm’.
Finally, I am challenged to declare my associations with the
pharmaceutical industry. Of the endocrine agents I was involved in
the clinical trials of goserelin (ZEBRA trial), vorazole and
raloxifene as well as the Cancer Research Campaign under 50s
trial. I was initially on the International Steering committee (now
merged into Steering Committee) of ATAC. I have helped train the
UK sales force for Novartis and use all three available aromatase
inhibitors in my clinical practice. I have received sponsorship from
AstraZeneca, Novartis and Pharmacia (now Pfizer).
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